Personalised medicine aims to provide the right treatment to the right patient, at the right dose and at the right time. this paper discusses how the regulatory process for companion diagnostics might be improved to realise the potential of personalised medicine.
Eric Lawson, Linda Lebon, Anne Virginie Eggimann, Anne Dupraz-Poiseau
Activities to improve the regulatory framework for companion diagnostics step up
2010 - SCRIP Regulatory Affairs
Eric Lawson, Project Director
Eric Directs the design and implementation of global regulatory stratgies for the development of Medical Devices, including In Vitro Diagnostics (IVD) and Combination Products.
Anne-Virginie Eggimann, Executive Director
She focuses on the development of drugs and biologics services, including for cell and gene therapies. She has expertise in and works on the design and implementation of science‑based regulatory strategies. She manages multidisciplinary teams dedicated to complex and innovative medicinal products development, at all stages, including for personalized medicine.
Anne Dupraz Poiseau, Executive Vice President
She focuses on the development of services for cell , gene and tissue based medicinal products, medical devices (including in-vitro diagnostics), drug/device combination and borderline products. She has expertise in and works on the design and implementation of regulatory strategies.